asacol magasýruþolin tafla 400 mg
tillotts pharma ab - mesalazinum inn - magasýruþolin tafla - 400 mg
asacol magasýruþolin tafla 800 mg
tillotts pharma ab - mesalazinum inn - magasýruþolin tafla - 800 mg
asacol (mesalazine espl) tafla með breyttan losunarhraða 1600 mg
tillotts pharma ab - mesalazinum inn - tafla með breyttan losunarhraða - 1600 mg
metoject stungulyf, lausn í áfylltri sprautu 50 mg/ml
medac gesellschaft für klinische spezialpräparate gmbh - methotrexatum inn - stungulyf, lausn í áfylltri sprautu - 50 mg/ml
spiolto respimat innöndunarlausn 2,5/2,5 míkróg
boehringer ingelheim international gmbh* - tiotropii bromidum inn; olodaterolum hýdróklóríð - innöndunarlausn - 2,5/2,5 míkróg
fintepla
ucb pharma s.a. - fenfluramine hydrochloride - epilepsies, myoclonic - antiepileptics, - treatment of seizures associated with dravet syndrome as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older. fintepla is indicated for the treatment of seizures associated with dravet syndrome and lennox-gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older.
mycapssa
amryt pharmaceuticals dac - octreotide acetate - acromegaly - hinsveiflur og heilahimnubólur og hliðstæður - mycapssa is indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.
metojectpen (metoject) stungulyf, lausn í áfylltum lyfjapenna 7,5 mg
medac gesellschaft für klinische spezialpräparate gmbh - methotrexatum inn - stungulyf, lausn í áfylltum lyfjapenna - 7,5 mg
metojectpen (metoject) stungulyf, lausn í áfylltum lyfjapenna 20 mg
medac gesellschaft für klinische spezialpräparate gmbh - methotrexatum inn - stungulyf, lausn í áfylltum lyfjapenna - 20 mg
atrovent innúðalyf, lausn 20 míkróg/skammt
boehringer ingelheim international gmbh* - ipratropii bromidum inn - innúðalyf, lausn - 20 míkróg/skammt